CompletedPhase 2NCT05668754
Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH
Studying Idiopathic hypersomnia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zevra Therapeutics
- Principal Investigator
- Christopher Drake, PhDInvestigator
- Intervention
- Serdexmethylphenidate(drug)
- Enrollment
- 50 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2024
Study locations (30)
- Sleep Disorders Center Of Alabama, Birmingham, Alabama, United States
- Amr Daphne, Daphne, Alabama, United States
- Lakeview Clinical Research, Guntersville, Alabama, United States
- SOCAL Clinical Research, Huntington Beach, California, United States
- Stanford University, Redwood City, California, United States
- Sleep Medicine Specialists of California, San Ramon, California, United States
- SDS Clinical Trials, Inc, Santa Ana, California, United States
- Delta Waves, Inc., Colorado Springs, Colorado, United States
- Saint Francis Sleep Allergy and Lung Institute LLC, Clearwater, Florida, United States
- New Generation of Medical Trials, Hialeah, Florida, United States
- Angels Clinical Research, Miami, Florida, United States
- Ivetmar Medical Group, Miami, Florida, United States
- Somnology Research Associates, Miami, Florida, United States
- Clinical Trial Services, Corp, Miami, Florida, United States
- Pasadena Center for Medical Research, St. Petersburg, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Rho, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05668754 on ClinicalTrials.govOther trials for Idiopathic hypersomnia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07500090A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)Harmony Biosciences Management, Inc.
- RECRUITINGNCT06732284Study of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance TaskCentre Hospitalier Universitaire de Nīmes
- RECRUITINGPHASE2NCT07096674A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited
- RECRUITINGNANCT07006233A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic HypersomniaUniversity of Sydney
- RECRUITINGPHASE2NCT06843590A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaAlkermes, Inc.
- RECRUITINGPHASE2NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda
- RECRUITINGPHASE2, PHASE3NCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaAlkermes, Inc.
- RECRUITINGPHASE2NCT06752668A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited